20
Jul
2021

Rivus Gets $35M to Alter Mitochondria for T2D, NASH, Heart Failure & More

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

F-Prime Leads $60M Bet on Adela, Scanning the Methylome for Early Signs of Cancer